journal article·2025-04Open access

Reprogramming Lung Redox Homeostasis by NIR Driven Ultra‐Small Pd Loaded Covalent Organic Framework Inhibits NF‐κB Pathway for Acute Lung Injury Immunotherapy

Doudou Lei, Lin Liao, Tao Qin, Xiaoxuan Guan, Kunpeng Duan, Zhiwei Gao, Weiqian Jin, Mingjing Yin, Ke Zhang, Yan Liu, Yin Chen, Huyang Gao, Jiaxiao Li, Feifei Huang, Wenjing Liu, Chengde Xia, Bailei Wang, Hualin Huang, Shengqiu Lv, Qiang Zhi, Jiahao Huang, Ming Gao, Junyu Lu

Advanced Science· Volume 12· Issue 14

Abstract

Abstract Acute lung injury (ALI) refers to damage to lung related cells, typically caused by an uncontrollable inflammatory response, and over‐generated reactive oxygen species (ROS). Increasing evidence suggests that reprogramming lung redox homeostasis holds significant potentials for the clinical treatment of ALI. Herein, the simple synthesis of ultra‐small Pd loaded covalent organic framework (COF) (TP@Pd) is reported, which, when combined with near infrared (NIR) irradiation, exhibits nanozyme functionalities, including multiple enzyme mimicking activities and broad spectrum ROS scavenging, thereby promoting tissue repair for ALI immunotherapy. Mechanistically, through the therapeutic strategy of TP@Pd+NIR, the damaged cells and tissues are ameliorated by decreasing intracellular ROS levels (total ROS, ·OH and ·O 2 − ), downregulating inflammatory cytokines levels (IL‐6, TNF‐α and IL‐1β), upregulating antioxidant factor level (SOD2), inducing macrophage M2 directional polarization (downregulation of iNOS and CD86, and upregulation of IL‐10 and CD206), activating immunoregulation (CD4 + /CD8 + ratio increase), promoting tissue repair factor levels (upregulation of HSP70 and CD31), and suppressing the NF‐κB signaling pathway (downregulation of phosphorylated p65 and IκBα). Furthermore, following intravenous (IV) injection in rats, TP@Pd accumulated in lung tissue for 6 h, indicating the promising therapeutic efficacy via this administration route. Notably, the TP@Pd+NIR strategy demonstrated the excellent synergistic effects in alleviating lung inflammation storms, reducing diffuse alveolar damage, and accelerating lung tissue repair. Summarily, this work has designed a novel TP@Pd+NIR strategy for the synergistic enhancement of ALI amelioration, which may serve as a promising therapeutic approach for other ROS related diseases.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Covalent Organic Framework Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Intensive Care Unit The Second Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530 007 China

Department of Clinical Laboratory Key Laboratory of Clinical Laboratory Medicine of Guangxi Department of Education The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530 021 China

Department of Emergency Guangxi Medical University Cancer Hospital Nanning Guangxi 530 021 China

Life Sciences Institute Guangxi Medical University Nanning Guangxi 530 021 China

Department of Colorectal and Anal Surgery Department of Emergency The First Affiliated Hospital of Guangxi Medical University Nanning Guangxi 530 021 China

Plastic Surgery The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi 330 006 China

Department of Burns The First People's Hospital of Zhengzhou Zhengzhou 450 004 China

Department of Critical Care Medicine The Ninth Affiliated Hospital of Guangxi Medical University Beihai 536 000 China

Funding

National Natural Science Foundation of China

References (90)

Show source-provided references
1. 10.1038/s41581-018-0005-710.1038/s41581-018-0005-7 ↗
2. 10.1016/j.jare.2022.01.01410.1016/j.jare.2022.01.014 ↗
3. Xu J. Q. · Mil. Med. Res. · 2024 · 11 · 78
4. 10.1001/jama.2017.1768710.1001/jama.2017.17687 ↗
5. 10.1186/s12964-024-01620-y10.1186/s12964-024-01620-y ↗
6. 10.1183/16000617.0116-201610.1183/16000617.0116-2016 ↗
7. 10.1001/jama.2017.2190710.1001/jama.2017.21907 ↗
8. 10.1155/2022/636234410.1155/2022/6362344 ↗
9. 10.3390/antiox1203054810.3390/antiox12030548 ↗
10. 10.1002/wnan.176310.1002/wnan.1763 ↗
11. 10.1016/j.actbio.2022.06.02410.1016/j.actbio.2022.06.024 ↗
12. 10.1021/acscentsci.1c0086610.1021/acscentsci.1c00866 ↗
13. 10.1021/acsami.3c0736110.1021/acsami.3c07361 ↗
14. 10.1016/j.cclet.2023.10879310.1016/j.cclet.2023.108793 ↗
15. 10.1016/j.cclet.2021.03.07810.1016/j.cclet.2021.03.078 ↗
16. 10.1002/smll.20210351610.1002/smll.202103516 ↗
17. 10.1021/jacs.3c0825610.1021/jacs.3c08256 ↗
18. 10.1038/s41551-022-00846-w10.1038/s41551-022-00846-w ↗
19. 10.1039/D2SC05732H10.1039/D2SC05732H ↗
20. 10.1002/smll.20220089510.1002/smll.202200895 ↗
21. 10.1016/j.jcis.2023.05.01910.1016/j.jcis.2023.05.019 ↗
22. Jin Y.‐H. · Adv. Sci. · 2024
23. 10.1016/j.cclet.2023.10886510.1016/j.cclet.2023.108865 ↗
24. 10.1021/jacs.2c1301010.1021/jacs.2c13010 ↗
25. 10.1016/j.cej.2023.14187410.1016/j.cej.2023.141874 ↗
26. 10.1007/s40843-023-2560-810.1007/s40843-023-2560-8 ↗
27. 10.1021/acsami.1c0523410.1021/acsami.1c05234 ↗
28. 10.1021/acs.accounts.3c0038010.1021/acs.accounts.3c00380 ↗
29. 10.1039/D0CS00793E10.1039/D0CS00793E ↗
30. 10.1016/j.jcis.2022.05.02610.1016/j.jcis.2022.05.026 ↗
31. 10.1039/D1CS00559F10.1039/D1CS00559F ↗
32. 10.1016/j.bioactmat.2022.08.01610.1016/j.bioactmat.2022.08.016 ↗
33. 10.1039/D0NA00537A10.1039/D0NA00537A ↗
34. 10.1007/s40820-021-00696-210.1007/s40820-021-00696-2 ↗
35. 10.1016/j.bioactmat.2022.08.01610.1016/j.bioactmat.2022.08.016 ↗
36. 10.1021/acsami.3c1704810.1021/acsami.3c17048 ↗
37. 10.1002/adhm.20200209010.1002/adhm.202002090 ↗
38. 10.1002/adfm.20210180410.1002/adfm.202101804 ↗
39. 10.1021/acsami.2c1992110.1021/acsami.2c19921 ↗
40. 10.1002/EXP.2022014410.1002/EXP.20220144 ↗
41. 10.1038/s41467-023-36338-x10.1038/s41467-023-36338-x ↗
42. 10.1002/anie.20241009710.1002/anie.202410097 ↗
43. 10.1021/acsami.2c0773910.1021/acsami.2c07739 ↗
44. 10.1021/acsnano.3c0090610.1021/acsnano.3c00906 ↗
45. 10.1016/j.actbio.2024.08.03610.1016/j.actbio.2024.08.036 ↗
46. 10.1002/adma.20220592410.1002/adma.202205924 ↗
47. 10.1002/adhm.20230384210.1002/adhm.202303842 ↗
48. 10.1002/EXP.2022016110.1002/EXP.20220161 ↗
49. 10.1016/j.biomaterials.2024.12266510.1016/j.biomaterials.2024.122665 ↗
50. 10.1002/adma.20200659110.1002/adma.202006591 ↗
51. 10.1039/D3CS00087G10.1039/D3CS00087G ↗
52. 10.1126/sciadv.aat641310.1126/sciadv.aat6413 ↗
53. 10.1038/s41467-021-23306-610.1038/s41467-021-23306-6 ↗
54. 10.1016/j.cej.2020.12713610.1016/j.cej.2020.127136 ↗
55. 10.1186/s11671-015-1158-y10.1186/s11671-015-1158-y ↗
56. 10.1186/s12951-024-02570-w10.1186/s12951-024-02570-w ↗
57. 10.1016/j.ccr.2021.21429810.1016/j.ccr.2021.214298 ↗
58. 10.1021/jacs.3c1109210.1021/jacs.3c11092 ↗
59. 10.1002/smll.20240755310.1002/smll.202407553 ↗
60. 10.1002/anie.20230521210.1002/anie.202305212 ↗
61. 10.1002/adfm.20241286210.1002/adfm.202412862 ↗
62. 10.1002/advs.20220600910.1002/advs.202206009 ↗
63. 10.1002/adma.20230637610.1002/adma.202306376 ↗
64. 10.1016/j.apmt.2021.10131310.1016/j.apmt.2021.101313 ↗
65. 10.7150/thno.4978410.7150/thno.49784 ↗
66. 10.1016/j.apsb.2019.01.01510.1016/j.apsb.2019.01.015 ↗
67. 10.1038/s41467-019-14131-z10.1038/s41467-019-14131-z ↗
68. 10.1016/j.nantod.2015.06.00610.1016/j.nantod.2015.06.006 ↗
69. 10.1016/j.biomaterials.2019.05.00210.1016/j.biomaterials.2019.05.002 ↗
70. 10.1038/s41419-023-05954-210.1038/s41419-023-05954-2 ↗
71. 10.1126/science.aal353510.1126/science.aal3535 ↗
72. 10.1186/s12974-022-02549-010.1186/s12974-022-02549-0 ↗
73. 10.1016/j.redox.2023.10274610.1016/j.redox.2023.102746 ↗
74. 10.1021/acsnano.2c1010310.1021/acsnano.2c10103 ↗
75. 10.1016/j.jcis.2024.08.15410.1016/j.jcis.2024.08.154 ↗
76. 10.1002/advs.20230400210.1002/advs.202304002 ↗
77. 10.1016/j.mattod.2023.03.02410.1016/j.mattod.2023.03.024 ↗
78. 10.1002/smll.20240541710.1002/smll.202405417 ↗
79. 10.1155/2011/79263910.1155/2011/792639 ↗
80. 10.1016/j.biopha.2022.11351310.1016/j.biopha.2022.113513 ↗
81. 10.1038/s41467-024-48442-710.1038/s41467-024-48442-7 ↗
82. 10.1038/s41565-023-01366-710.1038/s41565-023-01366-7 ↗
83. 10.1016/j.rechem.2023.10114610.1016/j.rechem.2023.101146 ↗
84. 10.1016/j.etap.2015.02.01910.1016/j.etap.2015.02.019 ↗
85. 10.1186/s40635-020-00350-y10.1186/s40635-020-00350-y ↗
86. 10.33549/physiolres.93512310.33549/physiolres.935123 ↗
87. 10.1038/s41419-022-05121-z10.1038/s41419-022-05121-z ↗
88. 10.1038/s41418-021-00859-z10.1038/s41418-021-00859-z ↗
89. 10.1021/acsnano.2c1134610.1021/acsnano.2c11346 ↗
90. 10.1039/D2TB02319A10.1039/D2TB02319A ↗